Vital Signs - Taking Stock of the Next Generation of Medical Implant Technologies


USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This issue of Vital Signs, released on January 26, 2011, provides a strategic overview of the next generation of medical implant technologies. Additionally, a company spotlight is provided for Ardian, Inc., a novel catheter-based treatment company for diseases related to sympathetic hyperactivity, including hypertension, chronic kidney disease, insulin resistance and heart failure. Reimbursement and regulatory news from the FDA is also provided for the week of January 3, 2011.

Table of Contents

Vital Signs - Taking Stock of the Next Generation of Medical Implant TechnologiesVital Signs: 26 Jan 2011This week's issue

Related Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.